Aqualung Therapeutics

Aqualung Therapeutics is a private, clinical-stage biotech focused on high-need inflammatory and fibrotic diseases through its eNamptor™ platform. The company's lead asset, ALT-100, is a monoclonal antibody in Phase 2a development for Acute Respiratory Distress Syndrome (ARDS) and has received FDA clearance for a Phase 2a study in lung fibrosis. With recent non-dilutive funding from an NIH STTR grant and a pipeline targeting conditions with significant mortality, Aqualung is positioning itself in a large and underserved therapeutic market.

eNamptor™ platform targeting extracellular NAMPT (eNAMPT), a DAMP protein and TLR4 ligand that drives inflammation, vascular leak, and fibrosis. Includes a neutralizing monoclonal antibody (ALT-100) and biomarker tools.

The ARDS and pulmonary fibrosis spaces are highly competitive with numerous large pharma and biotech players investigating anti-inflammatory and anti-fibrotic mechanisms. Aqualung must demonstrate that targeting upstream eNAMPT offers differentiated efficacy or safety compared to agents targeting downstream cytokines or fibrotic pathways.